Seeing through the MIST: Abundance versus percentage. Commentary on metabolites in safety testing

Drug Metabolism and Disposition

Volumn 33, Issue 10, 2005, Pages 1409-1417

  Smith, Dennis A ^a   Obach, R Scott ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; AMITRIPTYLINE; AMPEROZIDE; BENOXAPROFEN; CARTEOLOL; CHLORMEZANONE; CITALOPRAM; CLOMIPRAMINE; DARIFENACIN; DOSULEPIN; EBROTIDINE; FENCLOFENAC; FIPEXIDE; FLUOXETINE; IMIPRAMINE; ISAXONINE; NEUROLEPTIC AGENT; NITREFAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIRPROFEN; PROPRANOLOL; QUINONE DERIVATIVE; RISPERIDONE; SERTRALINE; SIBUTRAMINE; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG; ZATOSETRON;

CHEMICAL STRUCTURE; DECISION MAKING; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXICITY TESTING;

ANIMALS; CLINICAL TRIALS; DECISION TREES; DRUG EVALUATION; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 24944563781     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005041     Document Type: Review

References (41)

1. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE, Williams SM, Greenfeder S, Billah M, Kreutner W, et al. (2002) Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 449:229-237.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
3. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, and Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 58:108-117.
4. Bakke OM, Wardell WM, and Lasagna L (1984) Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther 35:559-567.
5. Brasseur R, Vandenbosch C, Van den Bossche H, and Ruysschaert JM (1983) Mode of insertion of miconazole, ketoconazole and deacylated ketoconazole in lipid layers. A conformational analysis. Biochem Pharmacol 32:2175-2180.
6. Cahill SA and Gross GJ (2004) Propafenone and its metabolites preferentially inhibit 1Kr in rabbit ventricular myocytes. J Pharmacol Exp Ther 308:59-65.
7. + currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 124:663-668.
8. Chiu PJS, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, and Mitchell R (2004) Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 95:311-319.
9. Cohen ML, Bloomquist W, Schmid CR, Robertson DW, and Wong DT (1993) Zatosetron, a selective 5-HT3 receptor antagonist: pharmacological activities of human and animal metabolites. Drug Dev Res 29:209-215.
10. Danielsson BR, Skold AC, and Azarbayjani F (2001) Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des 7:787-802.
11. Dieckhaus CM, Miller TA, Sofia RD, and Macdonald TL (2000) A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab Dispos 28:814-822.
12. Finnell RH, Buehler BA, Kerr BM, Ager PL, and Levy RH (1992) Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 42 (Suppl 5):25-31.
13. Food and Drug Administration (1997) Guidance for Industry Q3B Impurities in New Drug Products. http://www.fda.gov/cder/guidance/1317fnl. htm#ATTACHMENT%20II (accessed March 28, 2005).
14. Harron DW, Goa KL, and Langtry HD (1991) Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 41:130-149.
15. Harrower ABD (1996) Pharmacokinetics of oral antihyperglycemic agents in patients with renal insufficiency. Clinical Pharmacokinetics 31:111-119.
16. James LP, Mayeux PR, and Hinson JA (2003) Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499-1506.
17. Jorga K, Fotteler B, Heizmann P, and Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-o-methyltransferase. Br J Clin Pharmacol 48:513-520.
18. Kerbusch T, Milligan PA, and Karlsson MO (2004) Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 57:176-180.
19. Kraemer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Boeger RH, Forssmann WG, Drexler H, and Schieffer B (2002) Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan. Role of the active metabolite EXP3179. Circ Res 90:770-776.
20. Lasser KE, Allen PD, Woolhander SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc 287:2215-2220.
21. Martz F, Failinger IIIC, and Blake DA (1977) Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther 203:231-239.
22. Mbai M, Rajamani S, and January CT (2002) The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. Cardiovasc Res 55:799-805.
23. Nilvebrant L (2002) Tolterodine and its active 5-hydroxylmethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol 90:260-267.
24. Nobile M and Vercellino P (1997) Inhibition of delayed rectifier K+ channels by phenytoin in rat neuroblastoma cells. Br J Pharmacol 120:647-652.
25. Oatis JE, Russell MP, Knapp DR, and Walle T (1981) Ring hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activites of the seven isomers. J Med Chem 24:309-314.
26. Owens MJ (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322.
27. Paakkari I (2002) Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127:279-284.
28. Park BK, Kitteringham NR, Powell H, and Pirmohamed M (2000) Advances in molecular toxicology - towards understanding idiosyncratic drug toxicity. Toxicology 153:39-60.
29. Raymond GV, Buehler BA, Finnell RH, and Holmes LB (1995) Anticonvulsant teratogenesis: 3. Possible metabolic basis. Teratology 51:55-56.
30. Rudorfer MV and Potter WZ (1997) The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 7:273-312.
31. Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, et al. (1999) Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 288:1151-1159.
32. Sanchez C and Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and receptor binding. Cell Mol Neurobiol 19:467-489.
33. Slattery JT, Wilson JM, Kalhorn TF, and Nelson SD (1987) Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin Pharmacol Ther 41:413-418.
34. Smith KS, Smith PL, Heady TN, Trugman JM, Harman WD, and MacDonald TL (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 16:123-128.
35. Svartengren J (1997) Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects. Biol Psychiatry 42:247-259.
36. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, and Annunziato L (1998) Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 54:113-121.
37. Vitols S (2003) Paracetamol hepatotoxicity at therapeutic doses. J Intern Med 253:95-98.
38. Watanabe K, Kawamura K, Yamashita S, Fujita S, Ishihara T, and Yabuuchi Y (1989) Effects on β-adrenoceptor of 8-hydroxycarteolol, main metabolite of β-adrenoceptor blocking agent carteolol. Oyo Yakuri 38:271-277.
39. Whitehouse LW, Menzies A, Mueller R, and Pontefract R (1994) Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94:81-95.
40. Williams M, Deecher DC, and Sullivan JP (1995) Drug receptors, in Burger's Medicinal Chemistry and Drug Discovery, 5th ed, vol 1 (Wolff ME ed) p 353, John Wiley & Sons, New York.
41. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, and Iga T (2002) Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D2 receptor occupancy. Synapse 46:32-37.